Endocrinology impacts almost every aspect of human health. Our world-class, in-house R&D organization continues to produce a deep pipeline of transformative novel molecules that are purposefully designed by harnessing our deep understanding of endocrine systems and patient burden, and with a committed and uncompromising pursuit of science and medicine. Learn more about our approach here: https://bit.ly/3W533dq
Crinetics Pharmaceuticals
Biotechnology Research
San Diego, California 17,389 followers
Discovering drugs for endocrine diseases and endocrine-related tumors. #acromegaly #crinetics #CarcinoidSyndrome
About us
This place is about more than a pharmaceutical career. It’s about making a real difference in the lives of patients. That’s why we’re here. That’s why you should maybe think about being here, too. Our mission is to build the leading endocrine company that consistently pioneers new therapeutics to help patients better control their disease and improve their daily lives. Working to accomplish this mission is how we bring our vision to life. For us, that vision is the best possible therapeutics available to all patients with diseases of the endocrine system. We love how that sounds. And we really can’t wait to know how it feels.
- Website
-
https://crinetics.com
External link for Crinetics Pharmaceuticals
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- San Diego, California
- Type
- Public Company
- Founded
- 2008
- Specialties
- Drug Discovery, Endocrinology, RareDisease, and Biotech
Locations
-
Primary
6055 Lusk Blvd
San Diego, California 92121, US
Employees at Crinetics Pharmaceuticals
Updates
-
As part of our commitment to improving care for #endocrine diseases, we launched AcromegalyTruth.com. This platform features research and patient perspectives on the challenges of treating #acromegaly. Designed with healthcare professionals in mind, this site aims to deepen the understanding of the patient experience. Explore the site and discover the truth about acromegaly: https://bit.ly/4bhU25j
-
Congenital adrenal hyperplasia (CAH) is a rare endocrine disorder with significant unmet needs, impacting approximately 1 in 10,000 to 15,000 live births in the U.S. and Europe. Our Co-founder and Chief Scientific Officer, Stephen Betz, reflects on Crinetics' commitment to addressing the urgent needs of the CAH community. #CAHAwarenessMonth
-
“The privilege to come to work each day and collaborate with such a fantastic, creative, and motivated team knowing that we are all working so hard to help people is what excites and inspires me the most about working at Crinetics.” – Michael Johns, Senior Scientist 2, Drug Metabolism and Pharmacokinetics Meet Michael, this month's #EmployeeSpotlight: https://bit.ly/4ciR1Tg
-
Our CEO & Founder, R Scott Struthers, is an EY Entrepreneur Of The Year® 2024 Pacific Southwest Award winner! Scott’s visionary approach to transforming the lives of those impacted by endocrine-related disorders has earned him this prestigious honor. He joins an esteemed multi-industry community of other entrepreneurs who have driven their companies’ success, transformed their industries, and made a positive impact on their employees and communities! Let's celebrate this well-deserved recognition of Scott's leadership and our collective efforts that made this achievement possible. #EOYUS #EOYPACSW Learn more here: https://bit.ly/3VNrDzs
-
Last week at our San Diego headquarters, we had the privilege of hosting a panel discussion in recognition of #CAHAwarenessMonth. We were joined by the CARES Foundation, Inc and heard heartfelt stories from a patient and caregiver about how congenital adrenal hyperplasia has impacted their lives. Grateful to the CARES Foundation for their tireless efforts in raising awareness and supporting individuals living with #CAH. Together, we can make a meaningful difference!
-
At Crinetics, we believe education and empathy are keys to inclusion and belonging. We recently hosted a dynamic, multi-perspective panel discussion in celebration of #PrideMonth where we focused on what being an #LGBTQ ally truly means. Thank you to all of our panelists for sharing your perspectives, and we look forward to putting these learnings into action.
-
At Crinetics, we support people living with endocrine diseases. June is congenital adrenal hyperplasia (CAH) Month, and we encourage you to help us raise awareness of this difficult-to-manage condition. CAH affects the adrenal glands, resulting in hormonal imbalances that can be life-altering, or even life-threatening. There have been few medical advances for this disease over the last 70 years, but we’re committed to changing that with our unique drug discovery and development platform. For more information on our efforts, visit: https://bit.ly/3XghDQx
-
Our Chief Development Officer, Dana Pizzuti, MD, shares why #ENDO2024 is particularly exciting for Crinetics and highlights the encouraging strides we're making in our pipeline development.
-
At #ENDO2024 this past weekend, our Chief Commercial Officer, Jim Hassard, shared how Crinetics is addressing some of the most pressing challenges highlighted at this year's conference.